Telok Tablet 80/5 mg
Telmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Palmgen Science Co., Ltd.
MFDS item code 202005511 · Approved 2020.07.29
This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension, improvement of dyslipidemia, and inhibition of cardiovascular risk and progression of atherosclerosis
This medication is used for patients who need to take telmisartan and rosuvastatin together. Telmisartan reduces the risk of myocardial infarction, stroke, and death due to cardiovascular diseases in patients with essential hypertension and those at high risk for cardiovascular diseases. Rosuvastatin lowers blood cholesterol levels in patients with hypercholesterolemia or dyslipidemia when not controlled by diet and exercise alone, delaying the progression of atherosclerosis. Additionally, it helps reduce the risk of stroke, myocardial infarction, and revascularization in adult patients at high risk for cardiovascular diseases. The combination of these two components effectively manages hypertension and dyslipidemia, improving cardiovascular health.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered in combination with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medications may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience.
This medication can cause serious harm to the fetus and newborn, especially during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be taken by those who are allergic to this drug or its components, pregnant or potentially pregnant women, and breastfeeding women. Caution is required when taking this medication in patients with severely impaired liver or kidney function, certain genetic disorders, and a history of muscular diseases. Elderly patients, patients with high potassium levels, and patients with impaired liver function should take this medication with caution, and any symptoms such as muscle pain or weakness should be reported to healthcare professionals immediately. This medication may affect liver and kidney function, so regular blood tests and liver function tests are important. Drug interactions may occur with other medications, so inform your doctor or pharmacist of any current medications being taken. Caution is needed as dizziness or drowsiness may occur when driving or operating machinery. This medication should be kept out of reach of children and should not be transferred to other containers.
Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, indigestion, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorder, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased blood creatinine, increased blood uric acid, elevated CK levels, decreased hemoglobin, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, ear noise, petechiae, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis, palpitations, fatigue, nausea, lack of effect, facial edema, alopecia, conjunctivitis, petechiae, angioedema, thrombocytopenia, increased blood creatinine, acute renal failure, oliguria
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture. It is important to keep the storage temperature between 1 and 30 degrees Celsius at room temperature. Avoid storing it in extremely hot or cold areas.
Bright pink oval film-coated tablets
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Palmgen Science Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.